13F Holdings
中文EN

TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD

Pharmaceutical Preparations · NYSE · SEC CIK 818686 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-16.4%
TTM net income YoY-28.9%
TTM EPS YoY-29.5%
Revenue 3-yr CAGR-2.8%
Net income 3-yr CAGR—

Margins

Gross margin65.8%
Operating margin10.2%
Net margin3.6%
FCF margin8.8%
EBITDA margin17.3%

Returns

ROE6.6%
ROA1.3%
ROIC (approx.)32.1%
Asset turnover0.35x

Leverage & solvency

Liabilities / assets80.1%
Debt / equity0.00x
Current ratio0.95x
Interest coverage—

Cash quality & payout

Operating cash flow / net income3.50x
Accruals ratio-3.2%
Payout ratio—
Capex / revenue3.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$17.26B$16.54B$15.85B$14.93B$15.88B
Cost of revenue$8.32B$8.48B$8.20B$7.95B$8.28B
Gross profit$8.94B$8.06B$7.64B$6.97B$7.59B
R&D expense$1.01B$998.00M$953.00M$838.00M$967.00M
SG&A expense$1.29B$1.16B$1.16B$1.18B$1.10B
Operating income$2.16B-$303.00M$433.00M-$2.20B$1.72B
Interest expense$916.00M$1.00B$1.03B$930.00M$891.00M
Pretax income$1.22B-$1.28B-$624.00M-$3.16B$658.00M
Income tax-$180.00M$676.00M-$7.00M-$643.00M$211.00M
Net income$1.41B-$1.64B-$559.00M-$2.45B$417.00M
EBITDA$3.16B$756.00M$1.59B-$889.00M$3.05B
EPS (basic)1.23-1.45-0.50-2.200.38
EPS (diluted)1.21-1.45-0.50-2.200.38
Weighted avg. shares (diluted)1.16B1.13B1.12B1.11B1.11B
Balance sheet
Cash & equivalents$3.56B$3.30B$3.23B$2.83B$2.20B
Receivables$3.71B$3.06B$3.41B$3.70B$4.53B
Inventory$3.18B$3.01B$4.02B$3.83B$3.82B
Current assets$13.95B$12.55B$12.48B$12.05B$12.57B
PP&E, net$4.08B$4.58B$5.75B$5.74B$5.98B
Goodwill$16.00B$16.00B$17.18B$17.18B$17.63B
Intangibles$3.78B$4.42B$5.39B$6.27B$7.47B
Total assets$40.75B$39.33B$43.48B$44.01B$47.67B
Current liabilities$13.46B$12.80B$12.25B$11.47B$11.03B
Short-term debt$1.82B$1.78B$1.67B$2.11B$1.43B
Total liabilities$32.83B$33.61B$35.35B$35.41B$36.42B
Shareholders' equity$7.91B$5.37B$7.51B$7.80B$10.28B
Cash flow statement
Operating cash flow$1.65B$1.25B$1.37B$1.59B$798.00M
Capital expenditure$501.00M$498.00M$526.00M$548.00M$562.00M
Free cash flow$1.15B$749.00M$842.00M$1.04B$236.00M
Investing cash flow$737.00M$792.00M$968.00M$656.00M$1.52B
Financing cash flow-$2.15B-$1.79B-$1.91B-$1.49B-$2.17B
Depreciation & amortization$1.00B$1.06B$1.15B$1.31B$1.33B
Stock-based compensation$157.00M$123.00M$121.00M$124.00M$119.00M

Free plan shows the latest 5 periods; Pro shows all 19 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.